Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ctDNA vs. pathological markers

Marla Lipsyc-Sharf • 4 Jun 2022
ASCO 2022
General

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, reflects on the use of circulating tumor DNA (ctDNA) in clinical practice, which will be used alongside traditional pathological markers. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Marla Lipsyc-Sharf

0:49
Validating ctDNA-based approaches in clinical trials
Marla Lipsyc-Sharf • 4 Jun 2022
1:46
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Marla Lipsyc-Sharf • 4 Jun 2022

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals